SCHEMBL3985002

SCHEMBL3985002

Cc1ccc(Cn2nc(C)c3c(c(O)c4n3CCN(C)C4=O)c2=O)cc1C

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPBWR1 P48145 1/20 0.35
PKM P14618 1/20 0.33
PKLR P30613 1/20 0.33
PPARG P37231 1/20 0.32
PPARD Q03181 1/20 0.32
PPARA Q07869 1/20 0.32
LMNA P02545 2/20 0.31
KCNA5 P22460 1/20 0.31
PDE5A O76074 2/20 0.30
TP53 P04637 1/20 0.30
FAAH O00519 1/20 0.30
NQO1 P15559 1/20 0.30
PDE6D O43924 1/20 0.30
PDE6A P16499 1/20 0.30
PDE6G P18545 1/20 0.30
ADORA2B P29275 1/20 0.30
ADORA1 P30542 1/20 0.30
PDE6B P35913 1/20 0.30
PDE6C P51160 1/20 0.30
PDE6H Q13956 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3985863 0.89 PKM (0.35) NPBWR1PKMPKLRLMNATP53
SCHEMBL3981492 0.88 MAOB (0.40) PPARGLMNATP53ADORA1POLB
SCHEMBL3985346 0.88 PKM (0.36) PKMPKLRMEN1POLBKMT2A
SCHEMBL16253837 0.88 NPBWR1 (0.35) NPBWR1PKMPKLRPPARGPPARD
SCHEMBL3986662 0.88 GAA (0.38) PKMPKLRLMNAPDE5ATP53
SCHEMBL3992564 0.87 PDE5A (0.38) NPBWR1LMNAPDE5ATP53MEN1
SCHEMBL3983532 0.87 PKM (0.44) PKMPKLRTP53KMT2A
SCHEMBL3985461 0.87 PDE5A (0.39) PDE5APDE6DPDE6APDE6GADORA2B
SCHEMBL3985716 0.86 PDE5A (0.46) PKMLMNAPDE5AMEN1POLB
SCHEMBL3983972 0.85 RXFP1 (0.40) PKMPKLRADORA1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7538112-B2 HIV integrase inhibitors MERCK & CO., INC. (US) 2009-05-26 US claimed
US-20080287394-A1 Hiv Integrase Inhibitors MERCK & CO., INC. (US) 2008-11-20 US claimed
EP-1756114-B1 HIV INTEGRASE INHIBITORS MERCK SHARP & DOHME (US) 2014-11-19 EP disclosed
US-7538112-B2 HIV integrase inhibitors MERCK & CO., INC. (US) 2009-05-26 US disclosed
US-7538112-B2 HIV integrase inhibitors MERCK & CO., INC. (US) 2009-05-26 US disclosed
US-20080287394-A1 Hiv Integrase Inhibitors MERCK & CO., INC. (US) 2008-11-20 US disclosed
US-20080287394-A1 Hiv Integrase Inhibitors MERCK & CO., INC. (US) 2008-11-20 US disclosed
US-20080287394-A1 Hiv Integrase Inhibitors MERCK & CO., INC. (US) 2008-11-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287394-A1 Hiv Integrase Inhibitors DHPS, DPYD, TYMP NPBWR1 4361/4885PKM 1268/4885PKLR 519/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.